Bulletin N°6 – Just 2025

Vaccination news is particularly busy, the bulletin will include 2 pages.

On the side of the authorities. Moreover,

The latest DGS-Urgent message relating to the prevention of infections in Vrs for the next season is. Consequently, in many ways, disconcerting. Moreover, He recommends that the prevention campaign begins September 1st pour vaccination of pregnant women (Abrysvo®) as for the administration of The Beyfortus® monoclonal antibody. For example, in bulletin n°6 – just 2025 contradiction with the opinions of the CTV and several learned companies that had proposed that the campaign of maternal vaccination begins two months earlierto guarantee optimal coverage of newborns. Consequently, Remember that vaccination must be carried out Between the 32nd. Similarly, 36th week of amenorrheaand that the average pregnancy duration is 40 weeks. Moreover, To ensure a Effective protection of newborns during the epidemic peak expected between the November 1. Moreover, January 1mothers must be vaccinated at least a month before childbirth pdf (Lien 1)(235 KB) . Therefore, Delay the campaign in September therefore exhibits at a preventable vulnerability windowespecially for infants born in October. For example, at the very beginning of November. Similarly, In a context of Strong budgetary tensions on the health systemthis decision apparently justified by a concern for “simplicity”. In addition, risks leading to loss of efficiency (by bulletin n°6 – just 2025 limiting the real impact of the vaccination strategy) and unjustified expenses.

For your information. Meanwhile,

The ESPID Congress, Main meeting in pediatric vaccinology was held in Bucharest from May 26 to 30, 2025. Furthermore, Many studies have been presented concerning various vaccines. The French teams were particularly present on VRS and pneumococcal infections.

&#13.
• Bronchiolitis : during the 2024–2025 season, it was Type B which mainly circulated in France while the VRS type A was dominant the previous year. Nirsévimab’s real life efficiency has been confirmedboth on hospitalizations, 85% (CI95% = 80–88%), and on emergency passages, 83% (CI95% = 68–91%).

&#13.

• An Argentinian study confirmed Abrysvo®’s real life efficiency During the first six months of life for the prevention of respiratory infections due to the hospitalized Vrs (66.1%, CI95% = 33.1–83.3).

&#13.

• Since the implementation of nirsévimab, a significant reduction in the frequency of otitis has been reported for the 1^era bulletin n°6 – just 2025 times, and this is a French study: −48% in <6 months, −20% between 6 months and 1 year.

&#13.

• An analysis of serotypes responsible for invasive pneumococcal infections (IIP) in France shows that the prevenar 20® is, By far, the vaccine sold in pediatrics offering the best coverage. In addition, the proportion of IIP is comparable in children without underlying pathology and those with known comorbidity. However, among the 7 additional serotypes of the 20-Valent vaccine, the distribution is very different between the two groups.

&#13.

• Another French study carried out from the data from the SNDS, the pneumococcal CNR and a portage study showed that IIPs were more frequent during the VRS circulation period. In addition. the serotypes most often involved during this period were those considered to be theoretically the least pathogenic, highlighting the interactions between VRS and pneumococci.

On the product side

• Capvaxive® (MSD), Vaccine combined 21-Valent bulletin n°6 – just 2025 Against the pneumococcus intended for adults, obtained the European MA. Its serotypical composition is very different from VPCs Previous: 8 serotypes not included in Prevenar 20®et 7 excluded. It should soon be the subject of a recommendation for> 65 years as well as for patients with risk factors. in the same way as the Prevenar 20®.
• A new monoclonal antibody against the VRS, the Clesrovimab (Enflonsia®), Intended for newborns and infants, also obtained a MA. It should be available in France in a few months. Like the Nirsévimab, it targets protein F, but acts on a separate antigen site.
• Due to the rapid start of zona vaccination, supply tensions (probably short -lived) are reported for the Shingrix®.

&#13.

• For the 2025–2026 season, the HAS recommends the preferential use of the EFLUELDA® (Strongly dosed) or Fluad® (vaccine added to the MF59) as antigrippal vaccines for subjects> 65 yearsdue to their greatest efficiency. bulletin n°6 – just 2025 The Transparency Commission granted them an ASMR 4 to allow these 2 vaccines to be made available.
• The situation of Vaccines against chikungunya is complex. A first alive attenuated vaccine. DISCIFIED (Valneva), had obtained an AMM a few months ago, then was recommended in> 65 years (population at risk of serious forms) due to the intensity of the epidemic in Reunion. Due to the occurrence of several serious side effects. the FDA and CDCS recommended a break in using vaccination among> 60s and the French authorities withdrew> 65 years of the targets of the vaccination campaign in France, especially in Reunion and Mayotte. Another vaccine, the Vimkya® (Bavarian Nordic), was put on the market without reimbursement (price> € 165), without recommendation. Composed of viral pseudo-particles (like HPV vaccines), it is inert and could be better tolerated in the elderly.

In response to your questions.

Can we administer the injectable bulletin n°6 – just 2025 vaccine several times currently available against typhoid? The answer is yes. but this is a relevant question, especially since the prevention of typhoid fever regains interest in a context of increased resistance Salmonella typhi antibiotics (quinolones, C3G, azithromycin). The currently available injectable vaccine (Typhim VI) is an unconjugated polysaccharidic. modest efficiency (≈60 %), not very durable (a few years), without booster effect, with a theoretical hypothesis of hyporeactivity (as for pneumococcal vaccines and polysaccharide meningoccic) during the repetition of injections. However, studies to date do not show a significant drop in the immune response during spaced reminders. Reinjections at 3 years induce a modest but present anamnesic response, without apparent immunological tolerance (Kossaczka et al., Vaccine 1999 ; WHO Position Paper 2018). An oral living vaccine (VIVOTI®) is available in France for patients over 5 years old. It does not expose the risk of hypreactivity but is contraindicated in immunocompromised. bulletin n°6 – just 2025 Its effectiveness is comparable to the injectable vaccine. It is administered in three sockets (J1, J3, J5), at a total cost of 30 to 45 €. The future could come from more effective combined vaccines (> 80%), widely used in India and Pakistan.

Is infants’ vaccination by Prevenar 20® authorized? Yes, a European MA is issued in a 3 + 1 diagram, So no medico-legal obstacle. It is not yet recommended in France and is therefore not reimbursed. It is however the most suitable vaccine currently for invasive infants infections. If the vaccine has been prescribed by another doctor (as in your case). issued by a pharmacy, it is perfectly legitimate to make your young patient benefit. Non-controlling in children (and therefore non-reimbursement) for more than a year now. especially for risky subjects including sickle cell ethical problem and is not understandable. Indeed. these patients should be vaccinated regardless of bulletin n°6 – just 2025 the pneumococcal vaccine combined according to a 3+1 scheme corresponding to the European MA of the VPC 20. Serious infections due to serotypes contained in the 20. not in the 13 or 15 have occurred from the MA of the VPC 20 in this population while we have an effective means of prevention.

The mother of a 2-month-old patient was under anti-TNF treatment during pregnancy and after birth. Can it receive vaccines against rotaviruses (alive vaccines attenuated)? Yes. Rotavirus vaccination is safe in mothers infants who have received this type of treatment during their pregnancy or breastfeeding. The use of anti-TNF during pregnancy or breastfeeding had been considered as a precaution as a contraindication to rotavirus vaccination. However, a Canadian study (of which 85% of infants were breastfed) shows that this is not justified. Be careful this is not the case for the BCG !!!

Robert Cohen. François Vie le bulletin n°6 – just 2025 Sage, Joël Gaudélus, Franck Thollot, Pierre Bakhache, Pierre Bégué, Marie-Aliette Dommergues, Véronique Dufour, Hervé Haas, Isabelle Hau, Cécile Janssen, Maeva Lefebvre, Didier Pinquier, Anne-Sophie Romain, Georges Thiebault, Catherine Weil-Olivier, Odile Launay.

Trelogies an PDF